Supplemental Evidence and Data Request on Recurrent Nephrolithiasis in Adults and Children: Comparative Effectiveness of Preventive Medical Strategies, 99265-99267 [2024-28933]

Download as PDF Federal Register / Vol. 89, No. 237 / Tuesday, December 10, 2024 / Notices You may also submit your Privacy Act request electronically by filling out the required information at: https:// foia.federalreserve.gov/. the individual under evaluation’s separation from employment, or three years—whichever occurs first. Longer retention is authorized if required for business use. CONTESTING RECORD PROCEDURES: ADMINISTRATIVE, TECHNICAL, AND PHYSICAL SAFEGUARDS: Paper records are secured by lock and key and electronic files are stored on secure servers. The system has the ability to track individual user actions within the system. The audit and accountability controls are based on National Institute of Standards and Technology (NIST) and Board standards, which, in turn, are based on applicable laws and regulations. The controls assist in detecting security violations and performance or other issues in the system. Access to the system is restricted to authorized users within the Board who require access for official business purposes. Users are classified into different roles and common access and usage rights are established for each role. User roles are used to delineate between the different types of access requirements such that users are restricted to data that is required in the performance of their duties. Periodic assessments and reviews are conducted to determine whether users still require access, have the appropriate role, and whether there have been any unauthorized changes. NOTIFICATION PROCEDURES: khammond on DSK9W7S144PROD with NOTICES RECORD ACCESS PROCEDURES: The Privacy Act allows individuals the right to access records maintained about them in a Board system of records. Your request for access must: (1) contain a statement that the request is made pursuant to the Privacy Act of 1974; (2) provide either the name of the Board system of records expected to contain the record requested or a concise description of the system of records; (3) provide the information necessary to verify your identity; and (4) provide any other information that may assist in the rapid identification of the record you seek. Current or former Board employees may make a request for access by contacting the Board office that maintains the record. The Board handles all Privacy Act requests as both a Privacy Act request and as a Freedom of Information Act request. The Board does not charge fees to a requestor seeking to access or amend his/her Privacy Act records. You may submit your Privacy Act request to the—Secretary of the Board, Board of Governors of the Federal Reserve System, 20th Street and Constitution Avenue NW, Washington, DC 20551. VerDate Sep<11>2014 17:28 Dec 09, 2024 The Privacy Act allows individuals to seek amendment of information that is erroneous, irrelevant, untimely, or incomplete and is maintained in a system of records that pertains to them. To request an amendment to your record, you should clearly mark the request as a ‘‘Privacy Act Amendment Request.’’ You have the burden of proof for demonstrating the appropriateness of the requested amendment and you must provide relevant and convincing evidence in support of your request. Your request for amendment must: (1) provide the name of the specific Board system of records containing the record you seek to amend; (2) identify the specific portion of the record you seek to amend; (3) describe the nature of and reasons for each requested amendment; (4) explain why you believe the record is not accurate, relevant, timely, or complete; and (5) unless you have already done so in a related Privacy Act request for access or amendment, provide the necessary information to verify your identity. Jkt 265001 Same as ‘‘Access procedures’’ above. You may also follow this procedure in order to request an accounting of previous disclosures of records pertaining to you as provided for by 5 U.S.C. 552a(c). EXEMPTIONS PROMULGATED FOR THE SYSTEM: Certain portions of this system of records may be exempted from 5 U.S.C. 552a(c)(3), (d), (e)(1), (e)(4)(G), (H), and (I), and (f) of the Privacy Act pursuant to 5 U.S.C. 552a(k)(5). HISTORY: This SORN was previously published in the Federal Register at 73 FR 24984 at 25003–04 (May 6, 2008). The SORN was also amended to incorporate two new routine uses required by OMB at 83 FR 43872 (August 28, 2018). Board of Governors of the Federal Reserve System. Ann E. Misback, Secretary of the Board. [FR Doc. 2024–28926 Filed 12–9–24; 8:45 am] BILLING CODE 6210–01–P PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 99265 DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Healthcare Research and Quality Supplemental Evidence and Data Request on Recurrent Nephrolithiasis in Adults and Children: Comparative Effectiveness of Preventive Medical Strategies Agency for Healthcare Research and Quality (AHRQ), HHS. ACTION: Request for supplemental evidence and data submission. AGENCY: The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on Recurrent Nephrolithiasis in Adults and Children: Comparative Effectiveness of Preventive Medical Strategies, which is currently being conducted by the AHRQ’s Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review. DATES: Submission Deadline on or before January 9, 2025. ADDRESSES: Email submissions: epc@ ahrq.hhs.gov. Print submissions: Mailing Address: Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857. Shipping Address (FedEx, UPS, etc.): Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD 20857. FOR FURTHER INFORMATION CONTACT: Kelly Carper, Telephone: 301–427–1656 or Email: epc@ahrq.hhs.gov. SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and Quality has commissioned the Evidence-based Practice Centers (EPC) Program to complete a review of the evidence for Recurrent Nephrolithiasis in Adults and Children: Comparative Effectiveness of Preventive Medical Strategies. AHRQ is conducting this review pursuant to Section 902 of the Public Health Service Act, 42 U.S.C. 299a. The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for SUMMARY: E:\FR\FM\10DEN1.SGM 10DEN1 99266 Federal Register / Vol. 89, No. 237 / Tuesday, December 10, 2024 / Notices each of its reviews. In order to do so, we are supplementing the usual manual and electronic database searches of the literature by requesting information from the public (e.g., details of studies conducted). We are looking for studies that report on Recurrent Nephrolithiasis in Adults and Children: Comparative Effectiveness of Preventive Medical Strategies. The entire research protocol is available online at: https:// effectivehealthcare.ahrq.gov/products/ kidney-stones/protocol. This is to notify the public that the EPC Program would find the following information on Recurrent Nephrolithiasis in Adults and Children: Comparative Effectiveness of Preventive Medical Strategies helpful: D A list of completed studies that your organization has sponsored for this topic. In the list, please indicate whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number. D For completed studies that do not have results on ClinicalTrials.gov, a summary, including the following elements, if relevant: study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/ enrolled/lost to follow-up/withdrawn/ analyzed, effectiveness/efficacy, and safety results. D A list of ongoing studies that your organization has sponsored for this topic. In the list, please provide the ClinicalTrials.gov trial number or, if the trial is not registered, the protocol for the study including, if relevant, a study number, the study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes. D Description of whether the above studies constitute ALL Phase II and above clinical trials sponsored by your organization for this topic and an index outlining the relevant information in each submitted file. Your contribution is very beneficial to the Program. Materials submitted must be publicly available or able to be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on topics not included in the review cannot be used by the EPC Program. This is a voluntary request for information, and all costs for complying with this request must be borne by the submitter. The draft of this review will be posted on AHRQ’s EPC Program website and available for public comment for a period of 4 weeks. If you would like to be notified when the draft is posted, please sign up for the email list at: https://effectivehealthcare.ahrq.gov/ email-updates. The review will answer the following questions. This information is provided as background. AHRQ is not requesting that the public provide answers to these questions. urine chemistry, or genetic testing performed prior to treatment? b. Does effectiveness vary by blood or urine chemistry or genetic testing performed as followup after treatment is initiated? KQ 2: What are the comparative harms of preventive treatment with diet or pharmacologic agents in nonpregnant children and adults with history of nephrolithiasis? a. Do harms vary by stone composition, diet assessment, blood or urine chemistry, or genetic testing performed prior to treatment? b. Do harms vary by blood or urine chemistry or genetic testing performed as followup after treatment is initiated? KQ 3: What is the comparative effectiveness of surveillance imaging strategies in nonpregnant children and adults with history of nephrolithiasis? a. Does effectiveness vary with preventive treatment? b. Does effectiveness vary by timing of imaging? KQ 4: What are the comparative harms of surveillance imaging strategies in nonpregnant children and adults with history of nephrolithiasis? a. Do harms vary with preventive treatment? b. Do harms vary by timing of imaging? Key Questions (KQ) KQ 1: What is the comparative effectiveness of preventive treatment with diet or pharmacologic agents in nonpregnant children and adults with history of nephrolithiasis? a. Does effectiveness vary by stone composition, diet assessment, blood or Contextual Question (CQ) CQ 1: What is the natural history of kidney stone recurrence in children and adults? PICOTS (Populations, Interventions, Comparators, Outcomes, Timing, and Setting) khammond on DSK9W7S144PROD with NOTICES DETAILED INCLUSION AND EXCLUSION CRITERIA FOR SYSTEMATIC REVIEW Category Include Exclude Populations ............... All KQs: Nonpregnant children and adults with a history of nephrolithiasis. Interventions ............. KQ 1, 1a, 1b, 2, 2a, 2b: Dietary and/or pharmacological treatment, including dietary supplements and FDA-approved prescription or OTC drugs (Appendix A). KQ 1a, 2a: Eligible interventions along with evaluation of stone composition, dietary intake, genetic testing, or blood or urine chemistries before treatment is started. KQ 1b, 2b: Eligible interventions along with evaluation of genetic testing or blood and urine chemistries after treatment initiation. KQ 3, 3a, 3b, 4, 4a, 4b: Followup imaging when used for routine surveillance (CT scan, renal ultrasound, abdominal radiograph) to detect radiographic stone recurrence, size, composition, location, or shape. KQ 1, 1a, 1b, 2, 2a, 2b: Placebo, usual diet, no preventive treatment (for effectiveness); other eligible intervention (for comparative effectiveness). All KQs: Children and adults without a history of nephrolithiasis; pregnant persons; persons receiving treatment for acute renal colic or for stone removal or expulsion. KQs 1, 2: Nondietary and nonpharmacological interventions, including behavioral interventions aimed to improve treatment adherence; interventions for the acute treatment of kidney stones (e.g., surgery, lithotripsy, medical expulsion therapy). Prescriptions drugs and OTC medications that are not FDA-approved or available in the United States. KQ 3, 4: Imaging not used specifically for surveillance of kidney stones. Comparators ............. VerDate Sep<11>2014 17:28 Dec 09, 2024 Jkt 265001 PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 All KQs: No comparator (single arm study). E:\FR\FM\10DEN1.SGM 10DEN1 Federal Register / Vol. 89, No. 237 / Tuesday, December 10, 2024 / Notices 99267 DETAILED INCLUSION AND EXCLUSION CRITERIA FOR SYSTEMATIC REVIEW—Continued Category Outcomes ................. Timing ....................... Setting ...................... Study Designs, Publication Types, and Language. Include Exclude KQ 3, 3a, 3b, 4, 4a, 4b: Eligible followup imaging for routine surveillance of kidney stones, no followup imaging. All KQs: Patient-centered health outcomes: Incident symptomatic stones, urinary tract obstruction with acute renal impairment, end-stage renal disease, urinary tract infection, stone-removal procedures/surgery, procedure-related morbidity, emergency department visits and hospitalizations, quality of life, missed school or work, preventive treatment-related adverse events, imaging-related adverse events, serious adverse events, discontinuations due to adverse events. Intermediate outcomes: Growth of existing stones, incident radiographic stones, radiation exposure, incidental imaging findings. KQ 1, 3: Studies that measure outcomes at least 12 months after baseline. KQ 2, 4: Followup not limited. Outpatient clinical settings including primary care, urology, nephrology, or other specialty stone clinics; countries with HDI12 of very high (Appendix B). All KQs: Published in peer-reviewed literature, unpublished studies with enough information about methods to determine risk of bias; English language. RCTs; for comparisons lacking sufficient RCT evidence, NRSIs with concurrent comparator group and primary study aim/outcome to assess a dietary or pharmacologic intervention or surveillance imaging approach are eligible. KQ 1, 1a, 1b, 3, 3a, 3b: Blood or urine chemistry measures, urine supersaturation measures, acute pain. KQ 1, 3: Studies of less than 12-months duration. Inpatient settings; Countries with HDI other than very high. All KQs: Interrupted time series, case series, narrative reviews, editorials, and commentaries are not eligible; systematic reviews are not eligible but will be reviewed to determine whether any included studies are eligible. Studies with fewer than 30 participants at baseline per study arm. Studies published in languages other than English. KQ 2: Studies designed to report epidemiologic associations between dietary factors and stone incidence. CT = computed tomography; FDA = U.S. Food and Drug Administration; HDI = United Nations Development Programme Human Development Index; KQ = key question; NRSI = nonrandomized study of intervention; OTC = over-the-counter; RCT = randomized controlled trial. Dated: December 4, 2024. Marquita Cullom, Associate Director. SUPPLEMENTARY INFORMATION: Royalty-Free Starting Material (MVAclone 1) for the Clinical Development, Evaluation, and Commercialization of a Viable Mpox Vaccine [FR Doc. 2024–28933 Filed 12–9–24; 8:45 am] BILLING CODE 4160–90–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Materials; Availability for Access National Institute of Allergy and Infectious Diseases, National Institutes of Health, HHS. ACTION: Notice. AGENCY: The material listed below is owned by an agency of the U.S. Government and is available for transfer to achieve expeditious use and/or commercialization of results of federally funded research and development. FOR FURTHER INFORMATION CONTACT: Access information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852 by contacting Benjamin Hurley at 240–669–5092 or benjamin.hurley@nih.gov. khammond on DSK9W7S144PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:28 Dec 09, 2024 Jkt 265001 Worldwide, leading health authorities have cited the growing need for a commitment to equitable vaccine access and its role in curtailing future epidemics—a vision that cannot be realized without significant improvements in the speed, scale, and access of vaccine manufacturing and deployment in historically underserved regions. For at-risk populations and those with contraindications to commonly deployed vaccines, such initiatives are even more vital. Modified vaccinia virus Ankara (MVA), developed more than 30 years ago as a highly attenuated candidate smallpox vaccine, was recloned at the U.S. National Institute of Allergy and Infectious Diseases (NIAID) (referred to here as ‘‘MVA clone-1’’) from a 1974originating passage and evaluated for safety and immunogenicity in both normal and partially immune-deficient animals. Subsequent studies verified the protective ability of this attenuated vaccine against mpox in non-human primates, and clinical efforts since have resulted in FDA approval and PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 availability of a two-dose MVA vaccine in the U.S. In support of the global humanitarian effort to achieve equitable vaccine access and in light of the current public health emergency of international concern (PHEIC) declared by the World Health Organization in 2024—which has resulted in more than 500 deaths in the Democratic Republic of the Congo since the beginning of this year—the National Institute of Allergy and Infectious Diseases (NIAID) is seeking inquiries from parties interested in independent R&D and/or collaborative research to further develop, evaluate, and commercialize a viable mpox vaccine for distribution (particularly in developing nations/regions currently having minimal access to mpox vaccines) using NIH-provided starting material (MVA clone-1). While traditional licensing opportunities related to mpox detection are also available (e.g., antibodies, neutralization assays), NIAID will transfer the MVA clone-1 material in question on a royalty-free basis to qualified partners in an effort to combat the current PHEIC. In the event that NIAID has limited ability to distribute material, or if supply approaches exhaustion, priority will be given to collaborators with a proposed plan demonstrating, in E:\FR\FM\10DEN1.SGM 10DEN1

Agencies

[Federal Register Volume 89, Number 237 (Tuesday, December 10, 2024)]
[Notices]
[Pages 99265-99267]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-28933]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality


Supplemental Evidence and Data Request on Recurrent 
Nephrolithiasis in Adults and Children: Comparative Effectiveness of 
Preventive Medical Strategies

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Request for supplemental evidence and data submission.

-----------------------------------------------------------------------

SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is 
seeking scientific information submissions from the public. Scientific 
information is being solicited to inform our review on Recurrent 
Nephrolithiasis in Adults and Children: Comparative Effectiveness of 
Preventive Medical Strategies, which is currently being conducted by 
the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to 
published and unpublished pertinent scientific information will improve 
the quality of this review.

DATES: Submission Deadline on or before January 9, 2025.

ADDRESSES: 
    Email submissions: [email protected].
    Print submissions:

Mailing Address: Center for Evidence and Practice Improvement, Agency 
for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 
Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.): Center for Evidence and Practice 
Improvement, Agency for Healthcare Research and Quality, ATTN: EPC 
SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD 
20857.

FOR FURTHER INFORMATION CONTACT: Kelly Carper, Telephone: 301-427-1656 
or Email: [email protected].

SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and 
Quality has commissioned the Evidence-based Practice Centers (EPC) 
Program to complete a review of the evidence for Recurrent 
Nephrolithiasis in Adults and Children: Comparative Effectiveness of 
Preventive Medical Strategies. AHRQ is conducting this review pursuant 
to Section 902 of the Public Health Service Act, 42 U.S.C. 299a.
    The EPC Program is dedicated to identifying as many studies as 
possible that are relevant to the questions for

[[Page 99266]]

each of its reviews. In order to do so, we are supplementing the usual 
manual and electronic database searches of the literature by requesting 
information from the public (e.g., details of studies conducted). We 
are looking for studies that report on Recurrent Nephrolithiasis in 
Adults and Children: Comparative Effectiveness of Preventive Medical 
Strategies. The entire research protocol is available online at: 
https://effectivehealthcare.ahrq.gov/products/kidney-stones/protocol.
    This is to notify the public that the EPC Program would find the 
following information on Recurrent Nephrolithiasis in Adults and 
Children: Comparative Effectiveness of Preventive Medical Strategies 
helpful:
    [ssquf] A list of completed studies that your organization has 
sponsored for this topic. In the list, please indicate whether results 
are available on ClinicalTrials.gov along with the ClinicalTrials.gov 
trial number.
    [ssquf] For completed studies that do not have results on 
ClinicalTrials.gov, a summary, including the following elements, if 
relevant: study number, study period, design, methodology, indication 
and diagnosis, proper use instructions, inclusion and exclusion 
criteria, primary and secondary outcomes, baseline characteristics, 
number of patients screened/eligible/enrolled/lost to follow-up/
withdrawn/analyzed, effectiveness/efficacy, and safety results.
    [ssquf] A list of ongoing studies that your organization has 
sponsored for this topic. In the list, please provide the 
ClinicalTrials.gov trial number or, if the trial is not registered, the 
protocol for the study including, if relevant, a study number, the 
study period, design, methodology, indication and diagnosis, proper use 
instructions, inclusion and exclusion criteria, and primary and 
secondary outcomes.
    [ssquf] Description of whether the above studies constitute ALL 
Phase II and above clinical trials sponsored by your organization for 
this topic and an index outlining the relevant information in each 
submitted file.
    Your contribution is very beneficial to the Program. Materials 
submitted must be publicly available or able to be made public. 
Materials that are considered confidential; marketing materials; study 
types not included in the review; or information on topics not included 
in the review cannot be used by the EPC Program. This is a voluntary 
request for information, and all costs for complying with this request 
must be borne by the submitter.
    The draft of this review will be posted on AHRQ's EPC Program 
website and available for public comment for a period of 4 weeks. If 
you would like to be notified when the draft is posted, please sign up 
for the email list at: https://effectivehealthcare.ahrq.gov/email-updates.
    The review will answer the following questions. This information is 
provided as background. AHRQ is not requesting that the public provide 
answers to these questions.

Key Questions (KQ)

    KQ 1: What is the comparative effectiveness of preventive treatment 
with diet or pharmacologic agents in nonpregnant children and adults 
with history of nephrolithiasis?
    a. Does effectiveness vary by stone composition, diet assessment, 
blood or urine chemistry, or genetic testing performed prior to 
treatment?
    b. Does effectiveness vary by blood or urine chemistry or genetic 
testing performed as followup after treatment is initiated?
    KQ 2: What are the comparative harms of preventive treatment with 
diet or pharmacologic agents in nonpregnant children and adults with 
history of nephrolithiasis?
    a. Do harms vary by stone composition, diet assessment, blood or 
urine chemistry, or genetic testing performed prior to treatment?
    b. Do harms vary by blood or urine chemistry or genetic testing 
performed as followup after treatment is initiated?
    KQ 3: What is the comparative effectiveness of surveillance imaging 
strategies in nonpregnant children and adults with history of 
nephrolithiasis?
    a. Does effectiveness vary with preventive treatment?
    b. Does effectiveness vary by timing of imaging?
    KQ 4: What are the comparative harms of surveillance imaging 
strategies in nonpregnant children and adults with history of 
nephrolithiasis?
    a. Do harms vary with preventive treatment?
    b. Do harms vary by timing of imaging?

Contextual Question (CQ)

    CQ 1: What is the natural history of kidney stone recurrence in 
children and adults?

PICOTS (Populations, Interventions, Comparators, Outcomes, Timing, and 
Setting)

                         Detailed Inclusion and Exclusion Criteria for Systematic Review
----------------------------------------------------------------------------------------------------------------
              Category                              Include                                Exclude
----------------------------------------------------------------------------------------------------------------
Populations........................  All KQs: Nonpregnant children and      All KQs: Children and adults without
                                      adults with a history of               a history of nephrolithiasis;
                                      nephrolithiasis.                       pregnant persons; persons receiving
                                                                             treatment for acute renal colic or
                                                                             for stone removal or expulsion.
Interventions......................  KQ 1, 1a, 1b, 2, 2a, 2b: Dietary and/  KQs 1, 2: Nondietary and
                                      or pharmacological treatment,          nonpharmacological interventions,
                                      including dietary supplements and      including behavioral interventions
                                      FDA-approved prescription or OTC       aimed to improve treatment
                                      drugs (Appendix A).                    adherence; interventions for the
                                     KQ 1a, 2a: Eligible interventions       acute treatment of kidney stones
                                      along with evaluation of stone         (e.g., surgery, lithotripsy,
                                      composition, dietary intake, genetic   medical expulsion therapy).
                                      testing, or blood or urine             Prescriptions drugs and OTC
                                      chemistries before treatment is        medications that are not FDA-
                                      started.                               approved or available in the United
                                     KQ 1b, 2b: Eligible interventions       States.
                                      along with evaluation of genetic      KQ 3, 4: Imaging not used
                                      testing or blood and urine             specifically for surveillance of
                                      chemistries after treatment            kidney stones.
                                      initiation.
                                     KQ 3, 3a, 3b, 4, 4a, 4b: Followup
                                      imaging when used for routine
                                      surveillance (CT scan, renal
                                      ultrasound, abdominal radiograph) to
                                      detect radiographic stone
                                      recurrence, size, composition,
                                      location, or shape.
Comparators........................  KQ 1, 1a, 1b, 2, 2a, 2b: Placebo,      All KQs: No comparator (single arm
                                      usual diet, no preventive treatment    study).
                                      (for effectiveness); other eligible
                                      intervention (for comparative
                                      effectiveness).

[[Page 99267]]

 
                                     KQ 3, 3a, 3b, 4, 4a, 4b: Eligible
                                      followup imaging for routine
                                      surveillance of kidney stones, no
                                      followup imaging.
Outcomes...........................  All KQs: Patient-centered health       KQ 1, 1a, 1b, 3, 3a, 3b: Blood or
                                      outcomes: Incident symptomatic         urine chemistry measures, urine
                                      stones, urinary tract obstruction      supersaturation measures, acute
                                      with acute renal impairment, end-      pain.
                                      stage renal disease, urinary tract
                                      infection, stone-removal procedures/
                                      surgery, procedure-related
                                      morbidity, emergency department
                                      visits and hospitalizations, quality
                                      of life, missed school or work,
                                      preventive treatment-related adverse
                                      events, imaging-related adverse
                                      events, serious adverse events,
                                      discontinuations due to adverse
                                      events.
                                     Intermediate outcomes: Growth of
                                      existing stones, incident
                                      radiographic stones, radiation
                                      exposure, incidental imaging
                                      findings.
Timing.............................  KQ 1, 3: Studies that measure          KQ 1, 3: Studies of less than 12-
                                      outcomes at least 12 months after      months duration.
                                      baseline.
                                     KQ 2, 4: Followup not limited........
Setting............................  Outpatient clinical settings           Inpatient settings; Countries with
                                      including primary care, urology,       HDI other than very high.
                                      nephrology, or other specialty stone
                                      clinics; countries with HDI\12\ of
                                      very high (Appendix B).
Study Designs, Publication Types,    All KQs: Published in peer-reviewed    All KQs: Interrupted time series,
 and Language.                        literature, unpublished studies with   case series, narrative reviews,
                                      enough information about methods to    editorials, and commentaries are
                                      determine risk of bias; English        not eligible; systematic reviews
                                      language. RCTs; for comparisons        are not eligible but will be
                                      lacking sufficient RCT evidence,       reviewed to determine whether any
                                      NRSIs with concurrent comparator       included studies are eligible.
                                      group and primary study aim/outcome    Studies with fewer than 30
                                      to assess a dietary or pharmacologic   participants at baseline per study
                                      intervention or surveillance imaging   arm. Studies published in languages
                                      approach are eligible.                 other than English.
                                                                            KQ 2: Studies designed to report
                                                                             epidemiologic associations between
                                                                             dietary factors and stone
                                                                             incidence.
----------------------------------------------------------------------------------------------------------------
CT = computed tomography; FDA = U.S. Food and Drug Administration; HDI = United Nations Development Programme
  Human Development Index; KQ = key question; NRSI = nonrandomized study of intervention; OTC = over-the-
  counter; RCT = randomized controlled trial.


    Dated: December 4, 2024.
Marquita Cullom,
Associate Director.
[FR Doc. 2024-28933 Filed 12-9-24; 8:45 am]
BILLING CODE 4160-90-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.